Gabe Ortiz, MD, PhD

Rosenthal MA, Ranji SR, Kanzaria HK, Ortiz GM, Chase J, Chodos AH, Nguyen OK, Rodriguez EG, Makam AN. Characterizing patients hospitalized without an acute care indication: A retrospective cohort study. Journal of hospital medicine 2023. PMID: 36757173

Dana Freiser, BS, BA, RN, Merjo Roca, BA, RN, Tony Chung, PharmD,
Tanvi Bhakta, MSN, RN, CNL, Lisa G. Winston, MD, Gabriel M. Ortiz, MD, PhD. The Evolution of a Hospital-Based Covid-19 Vaccination Program for Inpatients NEJM Catalyst 2022. PMID:

Weiner J, Suwalski P, Holtgrewe M, Rakitko A, Thibeault C, Müller M, Patriki D, Quedenau C, Krüger U, Ilinsky V, Popov I, Balnis J, Jaitovich A, Helbig ET, Lippert LJ, Stubbemann P, Real LM, Macías J, Pineda JA, Fernandez-Fuertes M, Wang X, Karadeniz Z, Saccomanno J, Doehn JM, Hübner RH, Hinzmann B, Salvo M, Blueher A, Siemann S, Jurisic S, Beer JH, Rutishauser J, Wiggli B, Schmid H, Danninger K, Binder R, Corman VM, Mühlemann B, Arjun Arkal R, Fragiadakis GK, Mick E, Comet C, Calfee CS, Erle DJ, Hendrickson CM, Kangelaris KN, Krummel MF, Woodruff PG, Langelier CR, Venkataramani U, García F, Zyla J, Drosten C, Alice B, Jones TC, Suttorp N, Witzenrath M, Hippenstiel S, Zemojtel T, Skurk C, Wolfgang P, Borodina T, Pa-Covid SG, Ripke S, Sander LE, Beule D, Landmesser U, Guettouche T, Kurth F, Heidecker B. Increased risk of severe clinical course of COVID-19 in carriers of HLA-C*04:01. "Are Telehealth Visits Feasible for Vulnerable Patients?" 2021. PMID: 34490415

Sarma A, Christenson SA, Byrne A, Mick E, Pisco AO, DeVoe C, Deiss T, Ghale R, Zha BS, Tsitsiklis A, Jauregui A, Moazed F, Detweiler AM, Spottiswoode N, Sinha P, Neff N, Tan M, Serpa PH, Willmore A, Ansel KM, Wilson JG, Leligdowicz A, Siegel ER, Sirota M, DeRisi JL, Matthay MA, COMET Consortium, Hendrickson CM, Kangelaris KN, Krummel MF, Woodruff PG, Erle DJ, Calfee CS, Langelier CR. Tracheal aspirate RNA sequencing identifies distinct immunological features of COVID-19 ARDS. "Are Telehealth Visits Feasible for Vulnerable Patients?" 2021. PMID: 34446707

van der Wijst MGP, Vazquez SE, Hartoularos GC, Bastard P, Grant T, Bueno R, Lee DS, Greenland JR, Sun Y, Perez R, Ogorodnikov A, Ward A, Mann SA, Lynch KL, Yun C, Havlir DV, Chamie G, Marquez C, Greenhouse B, Lionakis MS, Norris PJ, Dumont LJ, Kelly K, Zhang P, Zhang Q, Gervais A, Le Voyer T, Whatley A, Si Y, Byrne A, Combes AJ, Rao AA, Song YS, Fragiadakis GK, Kangelaris K, Calfee CS, Erle DJ, Hendrickson C, Krummel MF, Woodruff PG, Langelier CR, Casanova JL, Derisi JL, Anderson MS, Ye CJ, UCSF COMET consortium. Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19. "Are Telehealth Visits Feasible for Vulnerable Patients?" 2021. PMID: 34429372

van der Wijst MGP, Vazquez SE, Hartoularos GC, Bastard P, Grant T, Bueno R, Lee DS, Greenland JR, Sun Y, Perez R, Ogorodnikov A, Ward A, Mann SA, Lynch KL, Yun C, Havlir DV, Chamie G, Marquez C, Greenhouse B, Lionakis MS, Norris PJ, Dumont LJ, Kelly K, Zhang P, Zhang Q, Gervais A, Voyer TL, Whatley A, Si Y, Byrne A, Combes AJ, Rao AA, Song YS, UCSF COMET consortium, Fragiadakis GK, Kangelaris K, Calfee CS, Erle DJ, Hendrickson C, Krummel MF, Woodruff PG, Langelier CR, Casanova JL, Derisi JL, Anderson MS, Ye CJ. Longitudinal single-cell epitope and RNA-sequencing reveals the immunological impact of type 1 interferon autoantibodies in critical COVID-19. "Are Telehealth Visits Feasible for Vulnerable Patients?" 2021. PMID: 33758859

Haber LA, Erickson HP, Ranji SR, Ortiz GM, Pratt LA. Acute Care for Patients Who Are Incarcerated: A Review. JAMA internal medicine 2019. PMID: 31524937

Devendra GP, Ortiz GM, Haber LA. By the Light of Day: Quality, Safety, and Education During the Overnight Admission Handoff. Cureus 2019. PMID: 31263637

Rosendale N, Goldman S, Ortiz GM, Haber LA. Acute Clinical Care for Transgender Patients: A Review. JAMA internal medicine 2018. PMID: 30178031

Block BL, Mehta T, Ortiz GM, Ferris SP, Vu TH, Huang L, Cattamanchi A. Unusual Radiographic Presentation of Pneumocystis Pneumonia in a Patient with AIDS. Case reports in infectious diseases 2017. PMID: 29362681

Haber LA, Ortiz GM. Clearing the air: inpatient providers' knowledge, perspectives, and experience with electronic cigarettes. Journal of hospital medicine 2014. PMID: 25352497

Seu L, Ortiz GM, Burt TD, Deeks SG, Martin JN, McCune JM. Levels of circulating myeloid subpopulations and of heme oxygenase-1 do not predict CD4(+) T cell recovery after the initiation of antiretroviral therapy for HIV disease. Volume 11. 2014. PMID: 25180041

Seu L, Ortiz GM, Epling L, Sinclair E, Swainson LA, Bajpai UD, Huang Y, Deeks SG, Hunt PW, Martin JN, McCune JM. Higher CD27+CD8+ T cells percentages during suppressive antiretroviral therapy predict greater subsequent CD4+ T cell recovery in treated HIV infection. Volume 8 of Issue 12. PloS one 2013. PMID: 24391889

Brown JN, Ortiz GM, Angel TE, Jacobs JM, Gritsenko M, Chan EY, Purdy DE, Murnane RD, Larsen K, Palermo RE, Shukla AK, Clauss TR, Katze MG, McCune JM, Smith RD. Morphine produces immunosuppressive effects in nonhuman primates at the proteomic and cellular levels. Molecular & cellular proteomics : MCP 2012. PMID: 22580588

Rakoff-Nahoum S, Kuebler PJ, Heymann JJ, E Sheehy M, Ortiz GM, S Ogg G, Barbour JD, Lenz J, Steinfeld AD, Nixon DF. Detection of T lymphocytes specific for human endogenous retrovirus K (HERV-K) in patients with seminoma. AIDS research and human retroviruses 2006. PMID: 16438646

Plana M, Garcia F, Oxenius A, Ortiz GM, Lopez A, Cruceta A, Mestre G, Fumero E, Fagard C, Sambeat MA, Segura F, Miró JM, Arnedo M, Lopalcos L, Pumarola T, Hirschel B, Phillips RE, Nixon DF, Gallart T, Gatell JM. Relevance of HIV-1-specific CD4+ helper T-cell responses during structured treatment interruptions in patients with CD4+ T-cell nadir above 400/mm3. Journal of acquired immune deficiency syndromes (1999) 2004. PMID: 15213562

Alexander TH, Ortiz GM, Wellons MF, Allen A, Grace EJ, Schweighardt B, Brancato J, Sandberg JK, Furlan SN, Miralles GD, Nixon DF, Bartlett JA. Changes in CD4+ T-cell differentiation phenotype during structured treatment interruption in patients with chronic HIV-1 infection. Journal of acquired immune deficiency syndromes (1999) 2003. PMID: 14657757

Karlsson AC, Deeks SG, Barbour JD, Heiken BD, Younger SR, Hoh R, Lane M, Sällberg M, Ortiz GM, Demarest JF, Liegler T, Grant RM, Martin JN, Nixon DF. Dual pressure from antiretroviral therapy and cell-mediated immune response on the human immunodeficiency virus type 1 protease gene. Journal of virology 2003. PMID: 12767994

García F, Plana M, Arnedo M, Ortiz GM, Miró JM, Lopalco L, Lori F, Pumarola T, Gallart T, Gatell JM. A cytostatic drug improves control of HIV-1 replication during structured treatment interruptions: a randomized study. AIDS (London, England) 2003. PMID: 12478068

Schweighardt B, Ortiz GM, Grant RM, Wellons M, Miralles GD, Kostrikis LG, Bartlett JA, Nixon DF. Emergence of drug-resistant HIV-1 variants in patients undergoing structured treatment interruptions. AIDS (London, England) 2002. PMID: 12441810

Ortiz GM, Hu J, Goldwitz JA, Chandwani R, Larsson M, Bhardwaj N, Bonhoeffer S, Ramratnam B, Zhang L, Markowitz MM, Nixon DF. Residual viral replication during antiretroviral therapy boosts human immunodeficiency virus type 1-specific CD8+ T-cell responses in subjects treated early after infection. Journal of virology 2002. PMID: 11739706

Ortiz GM, Wellons M, Brancato J, Vo HT, Zinn RL, Clarkson DE, Van Loon K, Bonhoeffer S, Miralles GD, Montefiori D, Bartlett JA, Nixon DF. Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects. Proceedings of the National Academy of Sciences of the United States of America 2001. PMID: 11687611

García F, Plana M, Ortiz GM, Bonhoeffer S, Soriano A, Vidal C, Cruceta A, Arnedo M, Gil C, Pantaleo G, Pumarola T, Gallart T, Nixon DF, Miró JM, Gatell JM. The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection. AIDS (London, England) 2001. PMID: 11416735

Bonhoeffer S, Rembiszewski M, Ortiz GM, Nixon DF. Risks and benefits of structured antiretroviral drug therapy interruptions in HIV-1 infection. AIDS (London, England) 2000. PMID: 11089619

Papasavvas E, Ortiz GM, Gross R, Sun J, Moore EC, Heymann JJ, Moonis M, Sandberg JK, Drohan LA, Gallagher B, Shull J, Nixon DF, Kostman JR, Montaner LJ. Enhancement of human immunodeficiency virus type 1-specific CD4 and CD8 T cell responses in chronically infected persons after temporary treatment interruption. The Journal of infectious diseases 2000. PMID: 10950770

Binley JM, Schiller DS, Ortiz GM, Hurley A, Nixon DF, Markowitz MM, Moore JP. The relationship between T cell proliferative responses and plasma viremia during treatment of human immunodeficiency virus type 1 infection with combination antiretroviral therapy. The Journal of infectious diseases 2000. PMID: 10762561

Ortiz GM, Nixon DF, Trkola A, Binley J, Jin X, Bonhoeffer S, Kuebler PJ, Donahoe SM, Demoitie MA, Kakimoto WM, Ketas T, Clas B, Heymann JJ, Zhang L, Cao Y, Hurley A, Moore JP, Ho DD, Markowitz M. HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy. The Journal of clinical investigation 1999. PMID: 10491418

Johnson WJ. Cell-free transfer of cholesterol from lysosomes to phospholipid vesicles. Journal of lipid research 1996. PMID: 8820102

Schmoldt A, Benthe HF, Haberland G. Digitoxin metabolism by rat liver microsomes. Biochemical pharmacology 1975. PMID: 10

Isaac O, Thiemer K. [Biochemical studies on camomile components/III. In vitro studies about the antipeptic activity of (--)-alpha-bisabolol (author's transl)]. Arzneimittel-Forschung 1975. PMID: 21

Byron HM. The ophthalmologist's office: planning and practice. Patient traffic flow and use of paramedical personnel. International ophthalmology clinics 1975. PMID: 340

Gabriel M. Ortiz and David Graham. “Acinetobacter in military personnel.” Case vignette as part of www.antimicrobe.org “Acinetobacter in military personnel.” Case vignette as part of www.antimicrobe.org . PMID: